Company Description
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; and sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases.
Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Country | United States |
| Founded | 1979 |
| IPO Date | Nov 5, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mark Emalfarb |
Contact Details
Address: 1044 North U.S. Highway One, Suite 201 Jupiter, Florida 33477-5094 United States | |
| Phone | 561 743 8333 |
| Website | dyadic.com |
Stock Details
| Ticker Symbol | DYAI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001213809 |
| CUSIP Number | 26745T101 |
| ISIN Number | US26745T1016 |
| Employer ID | 45-0486747 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark A. Emalfarb | Founder, Chief Executive Officer and Director |
| Joseph P. Hazelton | President and Chief Operating Officer |
| Ana Gómez Rodriguez | Secretary of the Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 25, 2026 | 10-K | Annual Report |
| Mar 6, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 424B5 | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Dec 29, 2025 | 8-K | Current Report |
| Dec 29, 2025 | 8-K | Current Report |